Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on March 23, 2016. The filing discloses the execution of new Executive Severance Agreements with the Company's CEO, CFO, and Senior Vice President of Development, replacing previous arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and severance terms rather than financial performance.
Material Changes
- New Severance Agreements: On March 23, 2016, the Company entered into new agreements with Brian M. Culley (CEO), Brandi L. Roberts (CFO), and R. Martin Emanuele (SVP, Development).
- Termination of Prior Plans: The Retention and Severance Plan dated July 21, 2009, was terminated. The Change in Control Severance Plan dated December 6, 2012, was amended to remove Ms. Roberts as a participant.
- Severance Terms:
- CEO (Mr. Culley): Eligible for 24 months of base salary and health insurance premiums upon a "Covered Termination." Stock options vest at 25% (or 100% if following a change in control). Exercise period extended to 12 months post-termination (or 10 years if following a change in control).
- CFO and SVP (Ms. Roberts and Dr. Emanuele): Eligible for 9 months of base salary and health insurance premiums. Stock options vest at 18.75% (or 100% if following a change in control). Exercise period extended to 9 months post-termination (or 10 years if following a change in control).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general risk factors. The primary contingency described is the eligibility for severance benefits, which is triggered only by an involuntary termination or resignation for "good reason" within 24 months of a change in control, subject to the execution of a general release of claims.
Investor Verification Checklist
- Verify the exact definitions of "involuntary termination" and "good reason" in the attached Exhibits 10.1, 10.2, and 10.3.
- Confirm the current base salary levels for the executives to calculate potential severance liabilities.
- Review the status of the Company's stock options to understand the impact of the accelerated vesting provisions.
- Check for any subsequent filings regarding a change in control that might trigger the enhanced vesting and exercise terms.